Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01467583 · ClinicalTrials.gov registry record · Phase 4
Fondaparinux in Critically Ill Patients With Renal Failure
A Phase 4 study, sponsored by Wayne State University.
- Completed
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
NCT01467583 is a Phase 4 study that has completed, run by Wayne State University. The registered enrollment target is 32 participants.
The verdict
NCT01467583, a Phase 4 study, has completed, sponsored by Wayne State University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine whether a dose-adjusted prophylaxis fondaparinux regimen of 2.5 milligrams (mg) subcutaneously administered every (q) 48 hours (hr) in patients with renal failure achieves peak and trough levels similar to patients with normal renal function, and protects patients from developing venous thromboembolism (VTE). Our hypothesis is that a dose-adjusted fondaparinux regimen, which extends the dosing interval from q24 to q48 hr, in patients with estimated creatinine clearance of \< 30 ml/min, will be safe and effective.
Interventions
- DRUG Fondaparinux
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2011-11 |
| Est. Completion | 2013-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01467583
The ClinicalTrials.gov registry entry for NCT01467583 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wayne State University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fondaparinux is the first listed.
NCT01467583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01467583 about?
NCT01467583 is a clinical study titled "Fondaparinux in Critically Ill Patients With Renal Failure". The primary objective of this study is to determine whether a dose-adjusted prophylaxis fondaparinux regimen of 2.5 milligrams (mg) subcutaneously administered every (q) 48 hours (hr) in patients with renal failure achieves peak and trough levels similar to patients with normal renal function, and p...
What is the current status of trial NCT01467583?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2011-11. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01467583?
The interventions under investigation include: Fondaparinux (DRUG).
Who is sponsoring clinical trial NCT01467583?
This trial is sponsored by Wayne State University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.